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Abstract
Background: Breast cancer outcome, including response to therapy, risk of metastasis and survival, is difficult to
predict using currently available methods, highlighting the urgent need for more informative biomarkers.
Androgen receptor (AR) has been implicated in breast carcinogenesis however its potential to be an informative
biomarker has yet to be fully explored. In this study, AR protein levels were determined in a cohort of 73 Grade III
invasive breast ductal adenocarcinomas.
Methods: The levels of Androgen receptor protein in a cohort of breast tumour samples was determined by
immunohistochemistry and the results were compared with clinical characteristics, including survival. The role of
defects in the regulation of Androgen receptor gene expression were examined by mutation and methylation
screening of the 5’ end of the gene, reporter assays of the 5’ and 3’ end of the AR gene, and searching for miRNAs
that may regulate AR gene expression.
Results: AR was expressed in 56% of tumours and expression was significantly inversely associated with 10-year
survival (P = 0.004). An investigation into the mechanisms responsible for the loss of AR expression revealed that
hypermethylation of the AR promoter is associated with loss of AR expression in breast cancer cells but not in
primary breast tumours. In AR negative breast tumours, mutation screening identified the same mutation (T105A)
in the 5’UTR of two AR negative breast cancer patients but not reported in the normal human population.
Reporter assay analysis of this mutation however found no evidence for a negative impact on AR 5’UTR activity.
The role of miR-124 in regulating AR expression was also investigated, however no evidence for this was found.
Conclusion: This study highlights the potential for AR expression to be an informative biomarker for breast cancer
survival and sets the scene for a more comprehensive investigation of the molecular basis of this phenomenon.
Keywords: Androgen receptor, Prognostic biomarker, Breast cancer, Gene regulation, Promoter methylation, Regu-
latory mutation, MiRNA
Background
Breast cancer is a heterogeneous disease comprising
tumour subtypes associated with variable clinical charac-
teristics [1]. Variables including tumour size, histological
subtype and grade, lymph node status and the expres-
sion of estrogen receptor alpha (ERa), progesterone
receptor (PR) and human epidermal growth factor
receptor 2 (HER2) currently assist routine clinical man-
agement [2]. However, these factors are limited in their
ability to predict individual survival and response to
therapy [2]. This is particularly apparent for patients
with advanced breast cancer, which is characterised by
high histological grade and the presence of lymph node
metastases, and has an aggressive clinical course and
generally a poor prognosis [2]. Identifying new prognos-
tic biomarkers and the molecular mechanisms underly-
ing breast cancer progression are paramount for
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developing improved therapeutic strategies.
Androgen receptor (AR) is a member of the nuclear
receptor superfamily and is known to be involved in a
complex network of signalling pathways that collectively
regulate cell proliferation [3,4]. Expressed in the normal
human mammary gland, where it predominantly loca-
lises to the inner layer of epithelial cells lining acini and
intralobular ducts [5], the role of AR in normal mam-
mary epithelial biology is unknown. AR has been impli-
cated in breast tumourigenesis, however delineating its
precise function has proven difficult with AR-mediated
androgenic effects shown to both stimulate and inhibit
growth of breast cancer cells [6,7]. The significance of
AR in human breast cancer is further emphasized by
the recent finding that it can be targeted in estrogen
receptor negative breast tumours [8]. Loss of AR expres-
sion is associated with early onset, high nuclear grade
and negative ER, PR and HER2 expression status in
breast tumours [9,10]. However, the mechanisms
responsible for this loss of AR expression in breast car-
cinogenesis remain unclear.
The AR gene comprises 9 exons spanning 180.25 kilo-
bases located on chromosome Xq12. Functional analyses
have identified two independently regulated transcrip-
tion initiation sites (TIS), AR-TIS I (-12/-11/-10) and
AR-TIS II (-1/+1) (Figure 1) [11]. Transcriptional initia-
tion from AR-TIS I is dependent on sequences located
between positions -17 and +45 and initiation from AR-
TIS II facilitated by a palindromic homopurine repeat
and SP1 binding to a GC-box [12,13]. Additional puta-
tive cis-acting elements include HL (helix-loop-helix-
like) motifs 1 and 2 [14] and a cAMP responsive ele-
ment [15]. Two CpG islands (CGI) are also located in
the AR promoter and extend into Exon 1. Hypermethy-
lation of these CGI have been shown to silence AR tran-
scription in prostate cancer cells and primary tumours
[16]. Genetic alterations in the promoter and 5’untrans-
lated regions (UTR) of the AR gene have been also
observed in prostate cancer cell lines, xenografts [17]
and in two prostate cancer patients [18,19]. In breast
cancer, the role of regulatory defects in the AR gene are
yet to be fully elucidated.
In this study, we show that loss of AR expression is
significantly associated with poor 10 year survival out-
come in Grade III invasive breast ductal adenocarcino-
mas. We then evaluated potential regulatory
mechanisms that may account for the loss of AR expres-
sion. For the first time we show that DNA hypermethy-
lation in the AR promoter is associated with loss of AR
expression in breast cancer cells, although this is not
t h ec a s ei no u rc o h o r to ft u m o u r sf r o mp a t i e n t sw i t h
Stage III breast cancer. We subsequently assessed
whether somatic mutations in AR regulatory regions or
miRNAs bioinformatically predicted to target the
human AR 3’UTR might contribute to the observed
changes in AR expression.
Results and Discussion
Low AR protein levels are associated with poor 10-year
survival in patients with Stage III breast cancer
To assess the prognostic value of AR expression in
breast cancer patients, IHC analysis was performed in a
cohort of 73 Grade III lymph node positive ductal ade-
nocarcinomas from patients with Stage III disease.
Patient and tumour characteristics are summarised in
Table 1. The patients ranged in age from 30 to 94 years
(mean, 54 years); with the majority of patients (97%)
aged over 35 years. AR expression was detected in 56%
(n = 41) of primary breast tumours. Positive expression
of ER, PR and HER2 was also observed in 55.5% (n =
40), 40% (n = 29) and 21.7% (n = 15) of breast tumours,
respectively. In AR-negative tumours, the majority (72%,
n = 23; 87%, n = 27; 86.6%, n = 26) were also ER, PR
and HER2 negative, respectively. The authors acknowl-
edge the potential limitations of TMA analysis, given
the inherent heterogeneity of tumour samples, but note
t h ee v i d e n c et h a tt h e r ei sah i g hc o n c o r d a n c eb e t w e e n
TMA cores and whole sections [20]. In addition the
impact was further minimized by analysing at least two
cores from each tumour, in accordance with the correla-
tion nomograms developed by Karlsson et al., 2009 [21].
AR expression was a significant prognostic factor for
overall patient survival (P = 0.004) (Figure 2). The 10-
year survival of patients with AR positive tumours was
52% versus 22% for patients with AR negative tumours.
This finding is consistent with previous studies in a
diversity of breast cancer patient populations wherein a
Figure 1 Schematic diagram of the human AR gene. The relative
positions of the two transcription initiation sites (TIS I and II) and
functionally known motifs; CpG islands, cAMP responsive element
(CRE), helix-loop-helix-like (HL) motifs, a palindromic homopurine
repeat (grey box) and GC-box (black box) which contains an SP1
binding site, are indicated (GenBank Accession No. NG009014.1). A
grey circle denotes the T105A alteration identified in two primary
breast tumours in the present study. DNA methylation was assessed
in Regions 1-4, as denoted by black lines. UTR, untranslated region.
ATG, translation start site.
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diagnosis, nuclear grade, recurrence-free survival was
observed [9,10,22-24].
DNA methylation of the AR promoter is associated with
low AR mRNA levels in breast cancer cell lines
To investigate potential mechanisms responsible for the
loss of AR expression, we evaluated the methylation sta-
tus of the AR promoter region and AR expression levels
in breast cancer cell lines. DNA methylation was deter-
mined by MS-HRM analysis of bisulfite treated DNA in
three regions; Regions 1 and 2 correspond to the CpG
island in the AR minimal promoter [14] and Region 3
corresponds to the CpG island at the translational start
site (Figure 1). DNA methylation was also assessed in a
further region, Region 4, by Sequenom MassARRAY
(Figure 1). Cell lines, MDAMB231, MCF7, MDAMB157,
MDAMB468 and MDAMB436 all showed between 25-
100% methylation in at least 2 of regions analysed (Fig-
ure 3a). Notably, methylation of the AR promoter region
was associated with the level of AR mRNA (Figure 3a
and 3b). A similar association has been observed in
prostate cancer, where treatment of prostate cancer cell
lines that display AR hypermethylation with the
demethylating agent 5-aza-2’-deoxycytidine induces the
re-expression and function of AR [25].
AR promoter methylation is not associated with low AR
protein levels in primary breast tumours
To examine whether AR promoter methylation is also
associated with loss of AR protein levels in breast
tumours, the DNA methylation status of Region 4,
which contains six CpG dinucleotides, was assessed by
Table 1 Patient and tumour characteristics*
Factor AR negative n = 32
(%)
AR positiven = 41
(%)
Age (years)
≤35 1 (3.0) 1 (2.4)
≥35 31 (97.0) 40 (97.6)
Estrogen receptor
Negative 23 (72.0) 9 (22.5)
Positive 9 (28.0) 31 (77.5)
Progesterone
receptor
Negative 27 (87.0) 16 (39.0)
Positive 4 (13.0) 25 (61.0)
HER2
Negative 18 (85.7) 25 (75.8)
Positive 3 (14.3) 8 (24.2)
Triple negative
a
No 6 (28.6) 30 (90.9)
Yes 15 (71.4) 3 (9.1)
*All patients were diagnosed with Stage III disease, as defined in the Materials
and Methods section of the manuscript
aTriple negative breast cancer represents tumours displaying negative
expression for estrogen receptor, progesterone receptor and HER2 by IHC. AR,
androgen receptor; HER2, human epidermal growth factor receptor type 2.
Figure 2 Impact of Androgen Receptor expression on breast
cancer survival. Kaplan-Meier estimates of 10 year survival of
patients by AR expression for primary tumours. n denotes the
number of patient samples.
 
   Region 1  Region 2  Region 3  Region 4    DNA methylation 
# CpG's assessed   9  14  8  6      0-25% 
Cell line                 26-49% 
Universally Methylated                    50-74% 
MDAMB231                  75-100%
MCF7                    
MDAMB157                   
MDAMB468                   
MDAMB436                    
Hs578T                    
BT549                    
ZR751                    
T47D                    
 
b 
a 
Figure 3 DNA methylation of the AR gene is associated with
loss of AR protein expression in breast cancer cells. (a) DNA
methylation status of breast cancer cell lines. Three regions of AR
were assessed by MS-HRM, overlapping Regions 1 and 2 in the AR
minimal promoter and Region 3 at the translational start site (refer
to Figure 1). Region 4 was assessed by Sequenom MassARRAY. Data
represent the average of two independent experiments. (b)A R
mRNA expression in breast cancer cell lines was assessed by qPCR.
Expression is shown relative to b-actin and bars represent the mean
± standard deviation of two independent experiments.
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analysis as it can analyse methylation at each individual
CpG dinucleotide, reliably detecting methylation as low
as 5%, in a high-throughput manner [26]. Primer design
constraints meant that Region 4 of the AR promoter
(Figure 1) was selected for analysis, with DNA methyla-
tion of overlapping Regions 1 and 2 associated with AR
mRNA levels in breast cancer cell lines. DNA methyla-
tion was observed in breast cancer patients at each of
the six CpGs (Figure 4). However, with the exception of
CpG’s 1-3, at which methylation in most tumours was
greater than 30%, for the most part only low level
methylation (< 30%) was observed. Furthermore, no sig-
nificant association was observed in the average methy-
lation between AR negative and AR positive primary
breast tumours in our cohort at any of the six CpG
dinucleotides examined.
There are several plausible explanations for the lack of
association between promoter methylation and expres-
sion in primary breast tumours. There is the possibility
that a region outside that examined shows expression
associated methylation and indeed, there was an incom-
plete association between Region 4 methylation and AR
mRNA levels in breast cancer cells. Additionally,
another mechanism such as somatic mutation of these
regions, or aberrant targeting by a miRNA, may be
involved.
Identification of somatic mutations in the AR 5’UTR in AR
negative breast tumours
Somatic mutation of regulatory regions of the AR gene
is another potential mechanism responsible for reduced
AR expression in breast tumours. To address this possi-
bility, we sequenced the 5’ regulatory region of AR (-659
to +280) in breast cancer cell lines. Our results revealed
no sequence variations in MDAMB157, MDAMB231,
MDAMB436, MDAMB468, MCF7, T47D, ZR75-1,
Hs578T and BT549 cells. We also sequenced the AR
promoter region from -6 to +133 in 32 primary breast
tumours. Amplification of the AR promoter region from
-165 to -7, which corresponds to the homopurine repeat
and GC box (Figure 1), revealed a mutation (mRNA pos
105, T > A, Figure 1), mapping to the AR 5’UTR, in two
patients. This sequence variation does not correspond to
any known SNPs (GRCh37 reference primary assembly,
http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp) or, to
our knowledge, any previously reported AR variants.
To investigate the potential significance of the AR
5’UTR T105A variant, we performed bioinformatics ana-
lysis on the wild-type and variant sequence. In the wild-
type sequence the T position is invariant in mammals
and is a component of the binding site for RNApolII
(based on ChIP-seq data) and the predicted and con-
served binding site for several transcription factors,
including RUNX1, En1 and Pax6. Based on the currently
available ChIP-seq data however, there is currently no
evidence that these transcription factors bind to this
sequence in vivo. The substitution from T to A results
in an abolishment of these predicted sites and the crea-
tion of predicted and conserved binding sites for
NHLH1 (data not shown).
To experimentally address the effect of this variant on
5’UTR activity, we fused the 5’UTR upstream of the fire-
fly cDNA and downstream of either the AR or the SV40
promoter, in pGL3-basic and pGL3-promoter vectors,
respectively. The AR 5’UTR T105A sequence variant did
not have a negative impact on SV40 or AR driven repor-
ter activity in either MCF7 or T47D cells (Figure 5).
Instead, the AR 5’UTR T105A sequence variant actually
increased AR reporter driven activity in T47D cells (P =
0.0001) (Figure 5).
Figure 4 DNA methylation of an 115 bp region in the AR
promoter is not associated with loss of AR protein expression
in a selective group of primary breast tumours. Methylation of
six CpG dinucleotides in the AR promoter of AR positive (Pos) and
negative (Neg) Grade III breast tumours as determined by
Sequenom MassARRAY (Region 4, Figure 1). Due to cleavage
patterns, the average methylation was determined for CpG
dinucleotides 2 and 3. Each dot represents an individual patient. A
methylation value of 1.0 indicates a fully methylated amplicon,
while a value of 0.0 indicates a fully unmethylated amplicon.
Horizontal lines represent average cohort methylation.
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tumours identified the same alteration (chrX:66680703,
mRNA pos 105, T > A) in the AR 5’UTR of two breast
tumours. Examination of the functional importance of
this sequence variation however revealed that there was
no negative impact on the activity of the AR 5’UTR in
MCF7 or T47D cells. This suggests that this mutation is
unlikely to negatively affect the regulation of AR expres-
sion. However, particularly given the AR 5’UTR T105A
sequence variant significantly increased AR reporter dri-
ven activity in T47D cells, more complex studies, such
as analysing the consequence of this mutation in the
context of the entire AR gene and AR protein expres-
sion, will be required to firmly establish this. Although
further analysis of our tumours was constrained by the
availability and nature of the FFPE tumour material, it is
plausible that mutations that effect AR expression exist
outside the promoter region examined, particularly in
regions upstream of the AR 5’UTR and in the AR
3’UTR, which are reported to contain putative regula-
tory elements involved in controlling mRNA stability
[27]. A recent epidemiological meta-analysis of the AR
gene concluded that common polymorphisms in the AR
gene are not associated with breast cancer risk among
Caucasian women [19]. However, the functional signifi-
cance of these variants, the AR expression status and
survival outcome of these patients was not considered
in this study.
miR-124 does not regulate the AR 3’UTR in breast cancer
cells
MiRNAs are small non-coding RNAs of ~20nt in
length that are capable of modulating gene expression
post-transcriptionally. Many have been shown to act
as either oncogenes or tumour suppressor genes that
are crucial to the development of breast cancer metas-
tasis and survival outcome [28]. To address the possi-
bility that altered expression of AR is mediated by
differential expression of miRNAs, we screened the
AR 3’UTR for potential miRNA target sites. Bioinfor-
matic analysis revealed that miR-124 was the only
miRNA predicted to target the human AR 3’UTR
using miRanda and TargetScan. To examine whether
miR-124 regulates the expression of the AR transcript,
we used a reporter gene assay. MCF7 and T47D cells
were transfected with pcDNA 3.1(+)-mir-124 vector
and expression of miR-124 verified. Cells transfected
with pcDNA 3.1(+)-mir-124 expressed high levels of
mature miR-124 at 12, 24, 39 and 48 hr time intervals
post-transfection, whereas no endogenous expression
was detected in control-transfected cells (Figure 6a).
For luciferase assays, we co-transfected MCF7 and
T47D cells with pcDNA 3.1(+)-mir-124 vector with
the pSG5-AR 3’UTR vector. The introduction of the
AR 3’UTR into pSG5 luc significantly increased repor-
ter activity in MCF7 (P = 0.007) but not in T47D cells
(Figure 6b). miR-124 overexpression did not alter luci-
ferase activity of the AR 3’UTR construct in any of the
cell lines examined (Figure 6b). These results suggest
that miR-124 is unlikely to regulate AR expression in
these cells.
MiR-124 was the only miRNA predicted by two com-
monly used algorithms to target the AR 3’UTR. How-
ever, over-expression of miR-124 did not regulate AR
expression in MCF7 or T47D cells, which otherwise dis-
play no endogenous expression of this miRNA. This
suggests that either miR-124 is unable to regulate AR in
this particular experimental system, or that the predic-
tion not correct. There is certainly evidence suggesting
that although a plethora of targets are predicted for
miRNAs, that many of these are false positives [29].
There have been reports of other miRNAs regulating
the expression of AR, including miR-488 [30]. It would
be of interest to determine whether there is an associa-
tion between the levels of these miRNAs and AR in
Stage III breast cancer, and whether these miRNAs have
the potential to be informative biomarkers or therapeu-
tic targets for this disease. Interestingly, the inclusion of
the AR 3’UTR significantly increased reporter activity in
MCF7 but not in T47D cells suggesting the potential
Figure 5 Impact of the AR T105A 5’UTR variant.L u c i f e r a s e
reporter activities of pGL3 basic with the AR promoter (AR prom)
and pGL3 promoter vector which contains the SV40 promoter (SV40
prom) together with either the wild-type (WT) or T105A mutant
(MT) AR 5’UTR sequence in MCF7 and T47D cells. Data is shown
relative to the respective empty vector ± the standard error of the
mean (SEM) and was generated from three independent
experiments. ***P = 0.0001.
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scriptional regulation in breast cancer cells.
Conclusions
In this paper we show that AR expression is significantly
associated with 10-year survival outcome in patients
with Stage III breast cancer. To predict and potentially
address the poor survival outcome of patients with AR
negative breast tumours it is important to understand
the mechanism underlying the reduced AR expression.
Here we demonstrate for the first time that hypermethy-
lation of sections of the AR 5’ regulatory region is asso-
ciated with loss of AR expression in breast cancer cell
lines, although not in a small set primary tumours. We
describe a new somatic mutation in the AR 5’UTR
which is found in two independent tumours and is not
a normal polymorphism. This study highlights the
potential for AR expression to be an informative prog-
nostic biomarker for breast cancer survival and sets the
scene for a more comprehensive investigation of the
molecular basis of this phenomenon.
Methods
Breast cancer cell lines
Breast cancer cell lines MDAMB157 (ER-PR-),
MDAMB231 (ER-PR-HER2-), MDAMB436 (ER-PR-),
MDAMB468 (ER-PR-), MCF7 (ER + PR + HER2-),
T47D (ER + PR + HER2-), ZR75-1 (ER + PR-), Hs578T
(ER-PR-HER2-), and BT549 (ER-PR-) were obtained
from American Type Culture Collection (ATCC) and
cultured according to the manufacturer’s recommenda-
tions. Hormone receptor status sourced from [31].
Clinical samples
Primary breast tumours were sourced from the Princess
Alexandra Hospital (Brisbane, Australia) following pro-
cedures endorsed by both The National Ethics Applica-
tion process of the National Health and Medical
Research Council of Australia (http://www.neaf.gov.au)
and The University of Queensland Human Ethics com-
mittee. Tumour tissues were formalin fixed and paraffin
embedded (FFPE), sectioned and stained using hematox-
ylin and eosin (H&E), and confirmed by a qualified
pathologist (G.D.F.) as invasive Grade III ductal adeno-
carcinomas. After the exclusion of patients for whom
there was no follow-up data, non-breast cancer asso-
ciated deaths and unreadable IHC expression, 73
patients were available for further analysis. None of the
patients had received preoperative radiochemotherapy.
The characteristics of the patients and tumours is
shown in Table 1, with the following definitions of
breast cancer stage III:
Stage IIIA
￿ no tumor is found in the breast. Cancer is found in
axillary lymph nodes that are attached to each other or
to other structures, or cancer may be found in lymph
nodes near the breastbone; or
￿ the tumor is 2 centimeters or smaller. Cancer has
spread to axillary lymph nodes that are attached to each
other or to other structures, or cancer may have spread
to lymph nodes near the breastbone; or
￿ the tumor is larger than 2 centimeters but not larger
than 5 centimeters. Cancer has spread to axillary lymph
a  
 
 
 
b  
Figure 6 miR-124 does not target the AR 3’U T Ri nb r e a s t
cancer cells. (a) miR-124 expression in MCF7 and T47D cells was
assessed by qPCR following transfection with pcDNA 3.1(+)-mir-124.
Expression is shown relative to RNU6B and dots represent the mean
± standard deviation of two independent experiments. (b)
Luciferase reporter activities relative to the Renilla internal control ±
the standard error of the mean (SEM) are shown. Data were
generated from three independent experiments. **P = 0.007.
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tures, or cancer may have spread to lymph nodes near
the breastbone; or
￿ the tumor is larger than 5 centimeters. Cancer has
spread to axillary lymph nodes that may be attached to
each other or to other structures, or cancer may have
spread to lymph nodes near the breastbone.
Stage IIIB
In stage IIIB, the tumor may be any size and cancer:
￿ has spread to the chest wall and/or the skin of the
breast; and
￿ may have spread to axillary lymph nodes that may
be attached to each other or to other structures, or can-
cer may have spread to lymph nodes near the
breastbone.
￿ Cancer that has spread to the skin of the breast is
inflammatory breast cancer. See the section on Inflam-
matory Breast Cancer for more information.
Stage IIIC
In stage IIIC, there may be no sign of cancer in the
breast or the tumor may be any size and may have
spread to the chest wall and/or the skin of the breast.
Also, cancer:
￿ has spread to lymph nodes above or below the col-
larbone; and
￿ may have spread to axillary lymph nodes or to
lymph nodes near the breastbone.
￿ Cancer that has spread to the skin of the breast is
inflammatory breast cancer. See the section on Inflam-
matory Breast Cancer for more information.
Stage IIIC breast cancer is divided into operable and
inoperable stage IIIC.
In operable stage IIIC, the cancer:
￿ is found in ten or more axillary lymph nodes; or
￿ is found in lymph nodes below the collarbone; or
￿ is found in axillary lymph nodes and in lymph nodes
near the breastbone.
￿ In inoperable stage IIIC breast cancer, the cancer
has spread to the lymph nodes above the collarbone.
Tissue microarray blocks and immunohistochemical
staining
Tumour-rich tissue from each biopsy was distinguished
from surrounding normal tissue in H&E-stained sections
by a qualified pathologist (G.D.F). Tissue microarrays
were constructed in duplicate from tumour-rich tissue
cores (1 mm × 0.6 mm) using an automated tissue
microarray (TMA) instrument (ATA-27; Beecher Instru-
ments). 4 μM sections of the TMA blocks were used for
immunohistochemical (IHC) analysis. Sections were
transferred on to glass slides, deparaffinised and immu-
nostained using anti-ER (SP1), anti-PR, (SP2), anti-
HER2/neu (4B5) (Ventana Medical Systems, pre-diluted)
or anti-AR (Biocare Medical, 1:50 dilution) antibodies,
and counterstained with 3,3’-Diaminobenzidine (DAB)
and hematoxylin. Staining was performed with the
BenchMark automated slide stainer (Ventana) using the
iVIEW DAB detection kit with additional Avidin and
Biotin Blockers according to the manufacturer’s instruc-
tions. Analysis of stained sections was performed by a
qualified pathologist (G.D.F) and the presence of tumour
tissue confirmed by examining the counterstain. Expres-
sion was scored as positive when visible staining ≥ 1%
was observed in the nucleus for ER, PR and AR. For
HER2 IHC was semiquantitatively evaluated with a
score of 3+ regarded as positive, 2+ as equivocal, and 1+
or 0 as negative. In instances of an equivocal evaluation,
silver-enhanced in situ hybridisation was performed as
previously described [32].
DNA methylation analysis
Genomic DNA was isolated from cell lines using the
NucleoSpin Tissue kit (MachereyNagel) according to the
manufacturer’s instructions. For each human tumour
sample, four FFPE tumour-rich tissue cores (1 mm ×
0.6 mm) were crushed and digested with proteinase K at
55°C for 2 days and treated with 20 mg RNase A for 1
hr at 37°C. DNA was isolated using the PureGene kit
(Qiagen) and subjected to bisulfite modification using
the MethylEasy Xceed kit (Human Genetic Signatures)
according to the manufacturer’s instructions.
PCR amplification and methylation sensitive high
resolution melt analysis (MS-HRM) was performed in
duplicate on the RotorGene™ Q (Qiagen). Primers were
designed according to the principles outlined in [33] to
control for PCR bias and are shown in Additional file 1:
Table S1. PCR was performed using 2 ng of bisulphite
modified template and standard PCR conditions, fol-
lowed by one cycle of 1 min 30 sec at 72°C and an MS-
HRM step from 70°C to 90°C rising by 0.1°C/sec. Bisul-
fite treated CpGenome™ Universal Methylated DNA
(Chemicon, Millipore) and DNA from T47D were used
as positive/methylated and negative/unmethylated con-
trols, respectively. The methylation status of these con-
trols was confirmed by direct sequencing of MS-HRM
products, purified using the QiaQuick Gel Extraction
Kit (Qiagen), performed by the Australian Genome
Research Facility (AGRF, Brisbane, Australia). To create
a range of methylated standards, these controls were
mixed in 25, 50 and 75% methylated to unmethylated
template ratios and were included in the analysis of
each region.
Sequenom MassARRAY DNA Methylation Analysis
Sequenom MassARRAY methylation analysis was per-
formed as described previously [26]. The forward primer
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mer has a T7-promoter tag (5-cagtaatacgactcactataggga-
gaaggct-3) (Additional file 1: Table S1). Bisulfite treated
CpGenome™ Universal Methylated DNA (Chemicon,
Millipore) and Whole genome amplified DNA prepared
as per instructions with the GenomePlex
® Complete
Whole Genome Amplification kit (Sigma) were used as
positive/methylated and negative/unmethylated controls,
respectively. Triplicate PCR reactions were pooled and
Shrimp Alkaline Phosphatase (Sequenom, San Diego)
treatment performed followed by transcription and RNa-
seA Cleavage for the T-cleavage reaction. Purified sam-
ples were nanodispensed onto silicon chips preloaded
with matrix (SpectroCHIPs; Sequenom, San Diego).
Mass spectra were collected using a MassARRAY mass
spectrometer (Bruker-Sequenom) and results analysed
by the EpiTYPER software V 1.0. Methylation readings
with overlapping signals and silent peaks were elimi-
nated from the calculation.
Quantitation of AR mRNA
To quantitate AR mRNA from cell lines, total RNA was
extracted using Trizol (Invitrogen). cDNA was synthe-
sised using 500 ng of RNA and Superscript First Strand
Synthesis System III (Invitrogen), according to the man-
ufacturer’s instructions. b-actin was used to normalise
mRNA concentration and primers are shown in Addi-
tional file 1: Table S1. Real-time PCR was performed in
d u p l i c a t eu s i n gt h eR o t o r G e n e ™ Q (Qiagen) using 50
cycles of standard PCR conditions.
Somatic mutation analysis
In breast cancer cell lines, a region spanning -659 to
+280 with respect to the start of transcription (+1) were
examined for somatic mutations. In FFPE tumours, the
fragmented nature and limited availability of DNA
meant that analysis was constrained to a smaller region
(-165 to +133) and was examined in the 32 tumours for
which IHC indicated negative AR expression. Primer
sequences are shown in Additional file 1: Table S1. PCR
was performed using KAPAHiFi DNA polymerase
(KAPA Biosystems, Geneworks, Australia) and 50 ng of
template using 30 amplification cycles as per the manu-
facturer’s instructions. PCR reactions were purified
using the QiaQuick Gel Extraction Kit (Qiagen) and
sequencing performed by AGRF (Brisbane, Australia).
Transcription factor binding site analysis
Bioinformatic analysis initially involved an analysis of
UCSC Genome Browser (http://genome.ucsc.edu). Tran-
scription factor binding sites were predicted by MOODS
(MOtif Occurrence Detection Suite) [34]. MOODS uses
the standard scoring model (log-odds against the back-
ground distribution) of PWMs. Scoring thresholds were
specified by P-value less than or equal to 0.01. We
tested T105A 5’UTR variant and WT sequences for
overlap with the TFBS models in the JASPAR database
[35]. TFBS logos were downloaded from the JASPAR
database web server: http://jaspar.cgb.ki.se/.
AR 5’UTR reporter assays
The AR 5’UTR T105A mutation was introduced into the
wild-type AR 5’UTR sequence (1116 bp, GenBank
Accession No. NG009014.1) by site-directed mutagen-
esis using a two-step PCR procedure using the primers
listed in Additional file 1: Table S1 and standard PCR
conditions. The AR 5’UTR wild-type and T105A mutant
alone and together with the AR promoter were cloned
into the HindIII/NcoI sites of pGL3-promoter and the
KpnI/NcoI sites of pGL3-basic (Promega), respectively.
Constructs were confirmed by sequencing performed by
AGRF (Brisbane, Australia).
MCF7 and T47D cells were transiently transfected
with 800 ng pGL3+/- either the SV40 or the AR promo-
ter, together with either the wild-type or mutant AR
5’UTR sequence and 100 ng Renilla reporter in a 24-
well plate, using Lipofectamine 2000 (Invitrogen). Forty-
eight hours after the initial transfections, relative lucifer-
ase activities were determined using the Dual-Glo luci-
ferase assay kit (Promega) and a DTX880 Multimode
Detector (Beckman Coulter) according to the manufac-
turer’s instructions. Statistical analysis was performed
using unpaired, two-tailed t tests, with p values < 0.05
considered significant.
miRNA analysis
Two algorithms, miRanda and TargetScan 5.1, were
used to predict target sites for miRNA in the AR 3’UTR
[36,37]. A total of 55 miRNA were predicted to target
AR, 12 of which have conserved seed sequences. Only
miR-124 was predicted by both algorithms. To quanti-
tate the expression of miR-124, total RNA from trans-
fected MCF7 and T47D cells was extracted using Trizol
(Invitrogen) and the expression of miR-124 determined
relative to RNU6B using the miScript PCR System
according to the manufacturer’s instructions (Qiagen).
AR 3’UTR reporter assays
The AR 3’UTR (436 bp; GenBank Accession No.
NG009014.1) was ligated downstream of the luciferase
coding sequence in the pSG5 vector (Stratagene). The
mir-124-1 stem-loop (84 bp; miRBase Accession No.
MI0000443) ± 200 bp of flanking sequences was cloned
into the KpnI/XbaI sites of the pcDNA 3.1(+) expression
vector (Invitrogen). MCF7 and T47D cells were transi-
ently transfected with 400 ng pcDNA 3.1(+) constructs,
200 ng pSG5-luciferase constructs and 10 ng of Renilla
reporter in a 24-well plate, using FuGene 6 (Roche).
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luciferase activities were determined using the Dual-Glo
luciferase assay kit (Promega) and a DTX880 Multimode
Detector (Beckman Coulter) according to the manufac-
turer’s instructions. Statistical analysis was performed
using unpaired, two-tailed t tests, with p values < 0.05
considered significant.
Statistical analysis
Survival time was calculated from the date of tumour
removal to the date of last follow-up or death attributa-
ble to breast cancer. Overall survival probabilities were
estimated non-parametrically with the use of the
Kaplan-Meier product limit method (GraphPad Prism
version 5.0a) and statistical significance accepted as P ≤
0.05.
Additional material
Additional file 1: Table S1. Oligonucleotide primers.
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